Is a single day patient friendly methyl aminolevulinate photodynamic therapy illumination scheme for superficial basal cell carcinoma feasible? A randomized multicenter pilot trial

Journal of Dermatological Treatment

Volumn 30, Issue 2, 2019, Pages 194-199

  Nguyen, K P ^a   Knuiman, G J ^a   Blokx, W A M ^a   Hoogedoorn, L ^a   Smits, T ^b   Gerritsen, M J P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MÁXIMA MEDICAL CENTER   (Netherlands)

Author keywords

fractionated illumination; methyl aminolevulinate; photodynamic therapy; Superficial basal cell carcinoma

Indexed keywords

AMINOLEVULINIC ACID METHYL ESTER; AMINOLEVULINIC ACID; METHYL 5-AMINOLEVULINATE; PHOTOSENSITIZING AGENT;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN TISSUE; ILLUMINATION; MALE; MULTICENTER STUDY; PHOTODYNAMIC THERAPY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SUPERFICIAL BASAL CELL CARCINOMA; TREATMENT FAILURE; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BASAL CELL CARCINOMA; CLINICAL TRIAL; MIDDLE AGED; PHOTOCHEMOTHERAPY; PROCEDURES; TUMOR RECURRENCE;

ADULT; AGED; AMINOLEVULINIC ACID; CARCINOMA, BASAL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PILOT PROJECTS;

EID: 85051969921     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546634.2018.1484558     Document Type: Article

References (36)

1. Flohil SC, de Vries E, Neumann HA, et al. Incidence, prevalence and future trends of primary basal cell carcinoma in the Netherlands. Acta Derm Venereol. 2011;91:24–30.
2. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166:1069–1080.
3. Housman TS, Feldman SR, Williford PM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol. 2003;48:425–429.
4. Arits AH, Schlangen MH, Nelemans PJ, et al. Trends in the incidence of basal cell carcinoma by histopathological subtype. J Eur Acad Dermatol Venereol. 2011;25:565–569.
5. Braathen LR, Szeimies RM, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol. 2007;56:125–143.
6. Morton C, Szeimies RM, Sidoroff A, et al. European Dermatology Forum Guidelines on topical photodynamic therapy. Eur J Dermatol. 2015;25:296–311.
7. Morton CA, Szeimies RM, Sidoroff A, et al. European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications–actinic keratoses, Bowen’s disease, basal cell carcinoma. J Eur Acad Dermatol Venereol. 2013;27:536–544.
8. Trakatelli M, Morton C, Nagore E, et al. Update of the European guidelines for basal cell carcinoma management. Eur J Dermatol. 2014;24:312–329.
9. Morton CA, McKenna KE, Rhodes LE. Guidelines for topical photodynamic therapy: update. Br J Dermatol. 2008;159:1245–1266.
10. Arits AH, Spoorenberg E, Mosterd K, et al. Cost-effectiveness of topical Imiquimod and fluorouracil vs. photodynamic therapy for treatment of superficial basal-cell carcinoma. Br J Dermatol. 2014;171:1501–1507.
11. de Haas ER, Kruijt B, Sterenborg HJ, et al. Fractionated illumination significantly improves the response of superficial basal cell carcinoma to aminolevulinic acid photodynamic therapy. J Invest Dermatol. 2006;126:2679–2686.
12. Star WM, van’t Veen AJ, Robinson DJ, et al. Topical 5-aminolevulinic acid mediated photodynamic therapy of superficial basal cell carcinoma using two light fractions with a two-hour interval: long-term follow-up. Acta Derm Venereol. 2006;86:412–417.
13. de Vijlder HC, Sterenborg HJ, Neumann HA, et al. Light fractionation significantly improves the response of superficial basal cell carcinoma to aminolaevulinic acid photodynamic therapy: five-year follow-up of a randomized, prospective trial. Acta Derm Venereol. 2012;92:641–647.
14. van der Veen N, van Leengoed HL, Star WM. In vivo fluorescence kinetics and photodynamic therapy using 5-aminolaevulinic acid-induced porphyrin: increased damage after multiple irradiations. Br J Cancer. 1994;70:867–872.
15. Van der Veen N, De Bruijn HS, Star WM. Photobleaching during and re-appearance after photodynamic therapy of topical ALA-induced fluorescence in UVB-treated mouse skin. Int J Cancer. 1997;72:110–118.
16. Robinson DJ, de Bruijn HS, de Wolf WJ, et al. Topical 5-aminolevulinic acid-photodynamic therapy of hairless mouse skin using two-fold illumination schemes: PpIX fluorescence kinetics, photobleaching and biological effect. Photochem Photobiol. 2000;72:794–802.
17. de Bruijn HS, de Haas ER, Hebeda KM, et al. Light fractionation does not enhance the efficacy of methyl 5-aminolevulinate mediated photodynamic therapy in normal mouse skin. Photochem Photobiol Sci. 2007;6:1325–1331.
18. Robinson DJ, de Bruijn HS, Star WM, et al. Dose and timing of the first light fraction in two-fold illumination schemes for topical ALA-mediated photodynamic therapy of hairless mouse skin. Photochem Photobiol. 2003;77:319–323.
19. de Bruijn HS, van der Ploeg-van den Heuvel A, Sterenborg HJ, et al. Fractionated illumination after topical application of 5-aminolevulinic acid on normal skin of hairless mice: the influence of the dark interval. J Photochem Photobiol B. 2006;85:184–190.
20. Angell-Petersen E, Sorensen R, Warloe T, et al. Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Invest Dermatol. 2006;126:265–271.
21. Peng Q, Moan J, Warloe T, et al. Build-up of esterified aminolevulinic-acid-derivative-induced porphyrin fluorescence in normal mouse skin. J Photochem Photobiol Biol B. 1996;34:95–96.
22. Fritsch C, Homey B, Stahl W, et al. Preferential relative porphyrin enrichment in solar keratoses upon topical application of delta-aminolevulinic acid methylester. Photchem Photbio. 1998;68:218.
23. Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med. 2015;88:167–179.
24. Kelleners-Smeets NW dHEBR, Ingels KJAO, Corten EML, et al. Evidence based richtlijn basaalcelcarcinoom (modulaire update 2014). 2014.
25. Arits AH, Mosterd K, Essers BA, et al. Photodynamic therapy versus topical Imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 2013;14:647–654.
26. Szeimies RM, Ibbotson S, Murrell DF, et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8–20 mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol. 2008;22:1302–1311.
27. Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol. 2008;18:547–553.
28. Morton CA. Methyl aminolevulinate (Metvix) photodynamic therapy–practical pearls. J Dermatol Treat. 2003;14:23–26.
29. Telfer NR, Colver GB, Morton CA. Guidelines for the management of basal cell carcinoma. Br J Dermatol. 2008;159:35–48.
30. Fantini F, Greco A, Del Giovane C, et al. Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response. J Eur Acad Dermatol Venereol. 2011;25:896–901.
31. Rhodes LE, de Rie MA, Leifsdottir R, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol. 2007;143:1131–1136.
32. Hoogedoorn L, Hendriks JC, Knuiman GJ, et al. Treatment failure in superficial basal cell carcinoma following treatment with photodynamic therapy: is this a result of underdiagnosis? J Eur Acad Dermatol Venereol. 2017;31:e50–ee2.
33. Nguyen KP, Knuiman GJ, van Erp PE, et al. Standard step sectioning of skin biopsy specimens diagnosed as superficial basal cell carcinoma frequently yields deeper and more aggressive subtypes. Am Acad Dermatol. 2017;76:351–353.e3.
34. Roozeboom MH, Arits AH, Mosterd K, et al. Three-year follow-up results of photodynamic therapy vs. Imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. J Invest Dermatol. 2016;136:1568–1574.
35. Longo C, Lallas A, Kyrgidis A, et al. Classifying distinct basal cell carcinoma subtype by means of dermatoscopy and reflectance confocal microscopy. J Am Acad Dermatol. 2014;71:716–724.e1.
36. Peppelman M, Wolberink EA, Blokx WA, et al. In vivo diagnosis of basal cell carcinoma subtype by reflectance confocal microscopy. Dermatology (Basel). 2013;227:255–262.